ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 37 • 2016 ACR/ARHP Annual Meeting

    Association Between Fibromyalgia and Bone Mineral Density: A Systematic Review and Meta-Analysis

    Sikarin Upala1 and Anawin Sanguankeo2, 1Internal Medicine, Bassett Medical Center, Cooperstown, NY, 2Bassett Medical Center, Cooperstown, NY

    Background/Purpose: Previous studies have shown that fibromyalgia syndrome (FMS) is associated with low level of physical activity and exercise, which may lead to an increased…
  • Abstract Number: 38 • 2016 ACR/ARHP Annual Meeting

    How Does Thiol/Disulphide Homeostasis Change in Fibromyalgia Patients?

    Bilge Ekinci1, Cemile Bicer2, Pervin Baran3, Sema Haliloglu4, Hulya Uzkeser5 and Ayse Carlioglu6, 1Physical Medicine and Rehabilitation, Erzurum Region Training and Research Hospital, Erzurum, Turkey, 2Biochemistry, Yildirim Beyazit University Medical Faculty, Ankara, Turkey, 3Biochemistry, Ataturk Training and Research Hospital, Ankara, Turkey, 4Physical Medicine and Rehabilitation, Maltepe Occupational Diseases Hospital, Istanbul, Turkey, 5Physical Medicine and Rehabilitation, Ataturk University Medical Faculty, erzuru, Turkey, 6Endocrinology, Erzurum Region Training and Research Hospital, Erzurum, Turkey

    Background/Purpose: Our aim was to investigate the thiol/disulphide homeostasis, which has an important role in many cellular activities such as antioxidant protection, detoxification, cell growth…
  • Abstract Number: 39 • 2016 ACR/ARHP Annual Meeting

    Effects of Pregabalin (Lyrica®) on Cerebrospinal Fluid Substance P in Human Subjects with Fibromyalgia Syndrome

    Irwin Jon Russell1, Joel E. Michalek2 and Sorleen Trevino-Mendez3, 1Affiliated with Arthritis & Osteoporosis Center of South Texas, Medical Director, Fibromyalgia Research and Consulting, San Antonio, Texas, San Antonio, TX, 2Professor, Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas, San Antonio, TX, 3Medical Student, Texas Tech University School of Medicine, Lubbock, TX

    Background/Purpose: Fibromyalgia Syndrome [FMS] is a common chronic pain disorder. Pregabalin (PGB) is one of three medications approved by the FDA for treatment of FMS.…
  • Abstract Number: 40 • 2016 ACR/ARHP Annual Meeting

    Lateral Epicondylitis Treatment: Comparison of Bandage, Laser Therapy and Extra-Corporeal Shock Wave Therapy

    Fatma Icyer1, Hulya Uzkeser2 and Saliha Karatay3, 1Physical Medicine and Rehabilitation,, Ataturk University,Faculty of Medicine, Erzurum, Turkey, 2Physical Medicine and Rehabilitation, Ataturk University Medical Faculty, erzuru, Turkey, 3Physiotherapy and Rehabilitation,, Faculty of Health Sciences, Gazi University, Ankara, Turkey

    Background/Purpose: Lateral epicondylitis is one of the most common conditions affecting elbow and characterized by a lesion of the common extensor tendon with or without…
  • Abstract Number: 41 • 2016 ACR/ARHP Annual Meeting

    Human Papilloma Virus Vaccination, Fibromyalgia and Dysautonomia

    Manuel Martínez-Lavín1, Paola-Kinara Reyes-Loyola2 and Laura-Aline Martinez-Martinez3, 1Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 2Rheumatology, National Institute of Cardiology, Mexico, Mexico, 3Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, TX, Mexico

    Background/Purpose: In a questionnaire-based case series, we described the clinical features of 45 patients who had the onset of a chronic illness soon after HPV…
  • Abstract Number: 42 • 2016 ACR/ARHP Annual Meeting

    Small  Fibre Neuropathy Biopsies (SFN)  in  Primary Fibromyalgia Revealed  Predominant Association with Metabolic Syndrome (in addition to other known treatable causes of SFN)  but No Clear Distinction Related to Biopsy Results

    Euthalia Roussou1, Johnathan Chan2, Istvan Bodi3 and Aleksandar Radunivics2, 1Rheumatology, Dr, London, United Kingdom, 2Neurologist, London, United Kingdom, 3Department of Clinical Neuropathology, London, United Kingdom

    Background/Purpose: To assess patients with primary fibromyalgia (pFM) for small fibre neuropathy (SFN) and to correlate biopsy results between groups and with known causes of…
  • Abstract Number: 43 • 2016 ACR/ARHP Annual Meeting

    Comorbid Development of Fibromyalgia and Posttraumatic Stress Disorder after Exposure to a Combat Environment

    Katrina Lawrence-Wolff1, Jay B. Higgs2, Douglas Williamson3, Stacey Young-McCaughan4, Jim Mintz4, Bernard Hildebrand1, Antoinette Brundige4, Kevin Kelly5, Adam Borah5, Brett Litz6, Elizabeth Hembree7, Alan Peterson4 and STRONG STAR Consortium, 1Rheumatology, San Antonio Military Medical Center, San Antonio, TX, 2Rheumatology, San Antonio Military Medical Center, Fort Sam Houston, TX, 3Duke Univeresity, Durham, NC, 4The University of Texas Health Science Center at San Antonio, San Antonio, TX, 5Carl R. Darnall Army Medical Center, Fort Hood, TX, 6VA Boston Healthcare System, Boston, MA, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Traumatic experiences are postulated mediators of the development of Fibromyalgia Syndrome (FMS). The STRONG STAR Consortium study of PTSD provides a unique opportunity to…
  • Abstract Number: 44 • 2016 ACR/ARHP Annual Meeting

    Ambroxol for Fibromyalgia. One-Group Pretest-Posttest Open Label Clinical Observation

    Laura-Aline Martinez-Martinez1, Luis-Fernando Perez2, Gumaro Acosta2, Lizbeth Becerril3, Pedro Rodriguez-Henriquez4, Omar-Eloy Muñoz-Monroy5, Luis H. Silveira6, Angelica Vargas Guerrero7 and Manuel Martínez-Lavín7, 1Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, TX, Mexico, 2National Institute of Cardiology, Mexico, Mexico, 3Hospital Juarez, Mexico, Mexico, 4Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 5Hospital Militar, Mexico City, Mexico, 6Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, 7Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico

    Background/Purpose: A consistent line of investigation proposes that fibromyalgia is a sympathetically maintained neuropathic pain syndrome. Moreover it has been suggested that dorsal root ganglia…
  • Abstract Number: 45 • 2016 ACR/ARHP Annual Meeting

    Small Fiber Neuropathy in Rheumatology Clinics

    Samy Metyas1, Ramy Messiah2, Tina Gettas2, Christina Chen3 and Daniel Arkfeld4, 1University of Southern California, Keck School of Medicine, Covina, CA, 2Research Associate, Covina Arthritis Clinic, covina, CA, 3Department of medicine, University of Southern California , Keck School of Medicine, Los Angeles, CA, 4Div of Rheumatology, Keck School of Medicine, University of Southern California-Los Angeles County Medical Center, Los Angeles, CA

    Background/Purpose: , Small Fiber Neuropathy (SFN) is a condition prevalent in patients with rheumatic diseases, particularly Fibromyalgia. The presence of neuropathic pain with normal nerve…
  • Abstract Number: 46 • 2016 ACR/ARHP Annual Meeting

    Novel Composite Responder Endpoints for Fibromyalgia Therapy Assessment

    R Michael Gendreau1, Lesley Arnold2, Daniel J. Clauw3, Judith Gendreau4, Bruce Daugherty4 and Seth Lederman4, 1Gendreau Consulting LLC, Poway, CA, 2University of Cincinnati, Cincinnati, OH, 3Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI, 4Tonix Pharmaceuticals, New York, NY

    Background/Purpose: Novel composite responder definitions for fibromyalgia (FM) clinical trials have been proposed by the Outcome Measures in Rheumatology (OMERACT) FM subcommittee.  These definitions which…
  • Abstract Number: 48 • 2016 ACR/ARHP Annual Meeting

    Fibromyalgia Impact Is a Potential Mediator for the Associations of Self-Efficacy and Pain Catastrophizing with Physical Functioning in Persons with Fibromyalgia

    Sun Yu1, Lori Lyn Price2, Jeffrey B. Driban1, William F. Harvey1 and Chenchen Wang1, 1Rheumatology, Tufts Medical Center, Boston, MA, 2Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA

    Background/Purpose: Fibromyalgia (FM) is a chronic multidimensional disorder that causes physical and psychological impairment, incurring significant healthcare costs. Self-efficacy and pain catastrophizing have been shown…
  • Abstract Number: 49 • 2016 ACR/ARHP Annual Meeting

    Efficacy of Mirogabalin on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase 2 Proof-of-Concept Study

    Domenico Merante1, Julio Rosenstock2, Uma Sharma3, Karen Feins4, Ching Hsu5 and Aaron Vinik6, 1Daiichi Sankyo Development Ltd, Gerrards Cross, Buckinghamshire, United Kingdom, 2Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, 3MMS Holdings Inc., Canton, MI, 4Daiichi Sankyo Pharma Development, Edison, NJ, 5Daiichi Sankyo Inc, Edison, NJ, 6Eastern Virginia Medical School, Norfolk, VA

    Background/Purpose: Mirogabalin is a novel, preferentially selective a2d-1 ligand intended for treatment of pain associated with fibromyalgia and neuropathic pain. Mirogabalin efficacy and safety was…
  • Abstract Number: 50 • 2016 ACR/ARHP Annual Meeting

    Tai Chi Significantly Modulates Resting State Functional Connectivity of the Cognitive Control Network in Fibromyalgia

    Jian Kong1, Kristen Jorgenson2, zengjian wang2, Emily Wolcott3, William F. Harvey4 and Chenchen Wang4, 1Massachusetts General Hospital, Boston, MA, 2MGH, Boston, MA, 3Tufts Medical Center, Boston, MA, 4Rheumatology, Tufts Medical Center, Boston, MA

    Background/Purpose:   Fibromyalgia (FM) is a common and complex musculoskeletal pain syndrome with unsatisfactory treatment options. Studies suggest that Tai Chi mind-body exercise may be…
  • Abstract Number: 62 • 2016 ACR/ARHP Annual Meeting

    Increased Frequency of Anti-Drug Antibodies in Patients Carrying Compatible IgG1 Allotypes and  Treated with Anti-TNF Antibodies

    Antonio Gonzalez1, Rosario Lopez-Rodriguez1, Ana Martinez2, Chamaida Plasencia-Rodriguez2, Andrea Jochems2, Dora Pascual-Salcedo2 and Alejandro Balsa2, 1Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 2Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain

    Background/Purpose:  One of the causes of insufficient response to biological drugs is the production of anti-drug antibodies (ADA) (1). These antibodies can decrease the effectiveness…
  • Abstract Number: 63 • 2016 ACR/ARHP Annual Meeting

    Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis

    James OIiver1, Darren Plant2, Gisela Orozco1, Samantha Smith1, Kimme L. Hyrich3, Ann Morgan4, John Isaacs5, Anthony G. Wilson6 and Anne Barton1,2, 1Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust, Manchester, United Kingdom, 3Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, 5Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, 6UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland

    Background/Purpose: Despite the revolutionary impact of TNF inhibitor (TNFi) therapy in rheumatoid arthritis (RA), up to 40% of patients fail to respond adequately. Whilst non-responder…
  • « Previous Page
  • 1
  • …
  • 1601
  • 1602
  • 1603
  • 1604
  • 1605
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology